skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Total body irradiation in non-Hodgkin's lymphoma. [Efficacy and complications]

Abstract

Between October 1972 and August 1977, low-dose fractionated total body irradiation (TBI), 150 to 300 rad,, was selected for 48 patients with previously untreated non-Hodgkin's lumphoma staged II, III, and IV. In 63% of the patients the disease had a nodular pattern; there were no patients with diffuse histiocytic lymphoma. All but 2 patients responded to TBI. The 4-year acutarial survival was 71% for the nodular group and 57% for the diffuse group. There were no acute symptoms during the course of treatment and no mortality associated with the treatment. Seventeen per cent of the patients developed transient platelet counts less than 30,000/mm/sup 3/. Four required hospitilization for correction of thrombocytopenia and/or infection. The majority of patients who failed more than 3 months after initial complete remission were placed back in remission with either chemotherapy, TBI, or local irradiation. Patients with persistent disease after TBI showed a less favorable response with chemotherapy. A selected group of 15 patients in relapse after chemotherapy or localized radiotherapy were treated with TBI. Eleven responded to treatment, while 4 showed no useful response. The median survival for this group was slightly over 2 years. Twenty percent developed transient platelet counts less than 30,000/mm/sup 3/.

Authors:
; ;
Publication Date:
Research Org.:
Univ. of Florida, Gainesville
OSTI Identifier:
5408200
Resource Type:
Journal Article
Journal Name:
Int. J. Radiat. Oncol., Biol. Phys.; (United States)
Additional Journal Information:
Journal Volume: 5:2
Country of Publication:
United States
Language:
English
Subject:
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.; 62 RADIOLOGY AND NUCLEAR MEDICINE; 59 BASIC BIOLOGICAL SCIENCES; BLOOD PLATELETS; BIOLOGICAL RADIATION EFFECTS; RADIOTHERAPY; SIDE EFFECTS; COBALT 60; DOSE RATES; EXPERIMENTAL DATA; FRACTIONATED IRRADIATION; GAMMA RADIATION; ISOLATED VALUES; LOW DOSE IRRADIATION; LYMPHOMAS; PATIENTS; WHOLE-BODY IRRADIATION; BETA DECAY RADIOISOTOPES; BETA-MINUS DECAY RADIOISOTOPES; BIOLOGICAL EFFECTS; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY FLUIDS; COBALT ISOTOPES; DATA; DATA FORMS; DISEASES; ELECTROMAGNETIC RADIATION; EXTERNAL IRRADIATION; INFORMATION; INTERMEDIATE MASS NUCLEI; INTERNAL CONVERSION RADIOISOTOPES; IONIZING RADIATIONS; IRRADIATION; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; MATERIALS; MEDICINE; MINUTES LIVING RADIOISOTOPES; NEOPLASMS; NUCLEAR MEDICINE; NUCLEI; NUMERICAL DATA; ODD-ODD NUCLEI; RADIATION EFFECTS; RADIATIONS; RADIOISOTOPES; RADIOLOGY; THERAPY; YEARS LIVING RADIOISOTOPES; 560151* - Radiation Effects on Animals- Man; 550603 - Medicine- External Radiation in Therapy- (1980-); 550900 - Pathology

Citation Formats

Thar, T.L., Million, R.R., and Noyes, W.D. Total body irradiation in non-Hodgkin's lymphoma. [Efficacy and complications]. United States: N. p., 1979. Web. doi:10.1016/0360-3016(79)90716-8.
Thar, T.L., Million, R.R., & Noyes, W.D. Total body irradiation in non-Hodgkin's lymphoma. [Efficacy and complications]. United States. doi:10.1016/0360-3016(79)90716-8.
Thar, T.L., Million, R.R., and Noyes, W.D. Thu . "Total body irradiation in non-Hodgkin's lymphoma. [Efficacy and complications]". United States. doi:10.1016/0360-3016(79)90716-8.
@article{osti_5408200,
title = {Total body irradiation in non-Hodgkin's lymphoma. [Efficacy and complications]},
author = {Thar, T.L. and Million, R.R. and Noyes, W.D.},
abstractNote = {Between October 1972 and August 1977, low-dose fractionated total body irradiation (TBI), 150 to 300 rad,, was selected for 48 patients with previously untreated non-Hodgkin's lumphoma staged II, III, and IV. In 63% of the patients the disease had a nodular pattern; there were no patients with diffuse histiocytic lymphoma. All but 2 patients responded to TBI. The 4-year acutarial survival was 71% for the nodular group and 57% for the diffuse group. There were no acute symptoms during the course of treatment and no mortality associated with the treatment. Seventeen per cent of the patients developed transient platelet counts less than 30,000/mm/sup 3/. Four required hospitilization for correction of thrombocytopenia and/or infection. The majority of patients who failed more than 3 months after initial complete remission were placed back in remission with either chemotherapy, TBI, or local irradiation. Patients with persistent disease after TBI showed a less favorable response with chemotherapy. A selected group of 15 patients in relapse after chemotherapy or localized radiotherapy were treated with TBI. Eleven responded to treatment, while 4 showed no useful response. The median survival for this group was slightly over 2 years. Twenty percent developed transient platelet counts less than 30,000/mm/sup 3/.},
doi = {10.1016/0360-3016(79)90716-8},
journal = {Int. J. Radiat. Oncol., Biol. Phys.; (United States)},
number = ,
volume = 5:2,
place = {United States},
year = {1979},
month = {2}
}